

Sun Yat-sen University Cancer Center IRB

中山大学肿瘤防治中心伦理委员会

审批号/Approval No: YP2008-06-5 审批日期/Approval Date: 2008-6-5

地址: 广州市越秀区东风东路 651 号 邮编: 510060 电话/Tel: 87343135 传真/Fax: 87343009
Address: 651, Dongfeng East Road, Guangzhou, China 510060

Protocol title: Study on clinical significance of MMS19 expression in pretreatment biopsied specimens of esophageal squamous cell carcinoma to efficacy of chemoradiotherapy: A single-institutional observational study

Protocol version & Date: 1.0, June 1, 2008

Informed consent version & Date: 1.0, June 1, 2008

Study site & Principle Investigator: Sun Yat-sen University Cancer Center & Guo-Liang Xu

The IRB of SYSUCC has discussed the proposal on June 5, 2008 in accordance to ICH GCP guidelines, government regulations and laws. Nine of eleven IRB members attended the meeting and agreed to approve this protocol.

Conditions: 1. Do not deviate from, or make changes to the study protocol without prior written IRB approval, except when it is necessary to eliminate immediate hazards to research subjects or when the change involves only logistical or administrative issues; 2. Report the following to SYSUCC IRB: (1) study protocol or consent document change, (2) serious adverse event, (3) study progress, and (4) new information that may be relevant to a subject's willingness to continue participation in the study; 3. Report study progress to SYSUC IRB at a 12-monthly interval until study closure.

Ya-Qi Zhang

IRB Chairman



Sun Yat-sen University Cancer Center

June 5, 2008